Ticagrelor Increases Risk of Death, Bleeding vs. Clopidogrel in Elderly ACS Patients, SWEDEHEART Analysis Shows
Ticagrelor also shows lower risk of MI, stroke in ACS patients 80 years and older
Ticagrelor and clopidogrel showed no difference in composite outcomes when used to treat elderly patients with acute coronary syndrome (ACS), but ticagrelor was associated with an increased risk of death and readmission for bleeding at 1 year after the index ACS admission, according to study results presented Tuesday at the European Society of Cardiology (ESC) 2020 virtual congress.